CELC Nasdaq

Celcuity Inc.

CELC | $16.4 -3.59% -3.72% 200K

(0.0% 1d) (-4.3% 1m) (70.6% 1y) (0.0% 2d) (0.0% 3d) (-5.9% 7d) (-31.48% volume)
Earnings Calendar: 2024-03-20
Market Cap: $ 499,431,168
http://www.celcuity.com
Sec Filling | Patents | 27 employees

Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

cancer tumor cells t-cell diagnostics ceiling

add to watch list Paper trade email alert is off

Press-releases

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
Published: 2024-04-04 (Crawled : 11:00) - globenewswire.com
CELC | $16.4 -3.59% -3.72% 200K

Commercial Services

| -11.82% | O: 4.4% H: 2.38% C: -2.45%

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-27 (Crawled : 20:00) - globenewswire.com
CELC | $16.4 -3.59% -3.72% 200K

Commercial Services

| -5.12% | O: -0.88% H: 23.27% C: 20.0%
year update financial results

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
Published: 2024-03-20 (Crawled : 11:00) - globenewswire.com
CELC | $16.4 -3.59% -3.72% 200K

Commercial Services

| -4.28% | O: 0.0% H: 1.61% C: -1.17%
year financial results

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
Published: 2024-03-06 (Crawled : 12:00) - globenewswire.com
CELC | $16.4 -3.59% -3.72% 200K

Commercial Services

| -5.33% | O: 1.15% H: 0.0% C: -1.2%
conference biopharma global

Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
Published: 2024-02-28 (Crawled : 12:00) - globenewswire.com
CELC | $16.4 -3.59% -3.72% 200K

Commercial Services

| 7.89% | O: -0.06% H: 2.04% C: -1.38%
conference health care

Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
Published: 2024-02-22 (Crawled : 21:00) - globenewswire.com
CELC | $16.4 -3.59% -3.72% 200K

Commercial Services

| 14.87% | O: 0.33% H: 3.46% C: 1.93%
first cancer treatment trial

Celcuity Appoints Eldon Mayer as Chief Commercial Officer
Published: 2024-02-20 (Crawled : 12:00) - globenewswire.com
CELC | $16.4 -3.59% -3.72% 200K

Commercial Services

| 13.06% | O: -1.05% H: 2.06% C: -4.51%
commercial

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
Published: 2023-12-06 (Crawled : 13:30) - globenewswire.com
CELC | $16.4 -3.59% -3.72% 200K

Commercial Services

| 14.87% | O: 0.47% H: 1.0% C: -0.53%
breast symposium cancer preclinical

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
Published: 2023-12-01 (Crawled : 17:00) - globenewswire.com
CELC | $16.4 -3.59% -3.72% 200K

Commercial Services

| 17.45% | O: -0.61% H: 3.57% C: 2.06%
breast symposium cancer preclinical

Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Published: 2023-11-22 (Crawled : 13:00) - globenewswire.com
CELC | $16.4 -3.59% -3.72% 200K

Commercial Services

| 33.57% | O: 2.02% H: 2.58% C: 0.46%
conference

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001062993-24-003329	4	2024-02-15	2024-02-13	Buy	A	5530	5530
0001062993-24-003326	4	2024-02-15	2024-02-13	Buy	A	7765	7765